- Active not recruitingPHASE3
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is testing new combinations of medicines (Nivolumab with Cabozantinib) against a standard treatment (Sunitinib) for kidney cancer that has spread. We want to see if the new combination is safer and works better for people who haven't had treatment before.
For: Renal Cell CarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
This study is testing a new medicine called ripretinib against an existing one, sunitinib, for people with advanced GIST. It's for those whose GIST has specific gene changes and has progressed after earlier treatment with imatinib.
For: GISTUnited States · Australia · Brazil - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
For: Papillary Renal Cell CarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study is for people with a type of cancer called GEP-NETs that has grown after previous treatment. It tests a new medicine, RYZ101, against standard treatments to see if it is safe and works better in stopping the cancer's growth.
For: GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor DiseaseUnited States · Belgium · Brazil - Active not recruitingPHASE2
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
This study looks at new medicines, Sunitinib and Temsirolimus, for rare cancers that haven't responded to usual treatments. The aim is to see if these medicines can shrink these specific types of cancer. It's a Phase II study, meaning it's still in the earlier stages of testing.
For: Advanced Rare TumoursCanada - RecruitingPHASE3
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This study looks into new ways to treat advanced stomach and gut cancers called GIST. It compares a new drug called CGT9486 (bezuclastinib) combined with an existing drug, sunitinib, against sunitinib alone, to see which works better for patients who haven't responded well to other treatments.
For: Advanced Gastrointestinal Stromal Tumors · Metastatic CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
For: Renal Cell CarcinomaUnited States · Australia · Austria - Active not recruitingPHASE3
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
This study compares two treatments, ripretinib and sunitinib, for advanced GIST (a type of cancer) in patients who have already been treated with imatinib. It aims to see which treatment works best.
For: Gastrointestinal Stromal TumorsUnited States · Argentina · Australia - RecruitingPHASE3
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
This study is testing a new drug, IDRX-42, for a type of cancer called GIST. It's for adults whose GIST has spread or can't be removed with surgery, and who have already tried another drug called imatinib. Researchers want to see if IDRX-42 works better and is safer than sunitinib.
For: Gastrointestinal NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
This study allows some cancer patients who are already benefiting from certain treatments in another study to continue receiving that treatment. It’s for those who wouldn't be able to get the treatment otherwise, helping them keep accessing therapies that are working for them.
For: CancerUnited States · Australia · Belgium